Abstract |
Kaposi's sarcoma (KS) is a vascular neoplasm typically observed in the immunocompromised patient populations, such as acquired immunodeficiency syndrome or transplant patients. KS can appear simultaneously at multiple sites as red to purple, maculo-papular or nodular cutaneous lesions sometimes showing a visceral extension. Sirolimus, an immunosuppressive agent with potent antitumor activity, has been effective in combating post-transplant KS. However, an aggressive regimen of immunosuppression for therapy of severe acute rejection episodes may abolish the antitumor effects of sirolimus. The following is a description of KS development under immunosuppressive therapy with sirolimus, and the successful treatment of KS lesions utilizing the topical application of imiquimod 5% cream, an immune response modifier.
|
Authors | N Babel, N Eibl, C Ulrich, G Bold, A Sefrin, M H Hammer, C Rosenberger, P Reinke |
Journal | Transplant infectious disease : an official journal of the Transplantation Society
(Transpl Infect Dis)
Vol. 10
Issue 1
Pg. 59-62
(Feb 2008)
ISSN: 1398-2273 [Print] Denmark |
PMID | 17428275
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Aminoquinolines
- Antineoplastic Agents
- Immunosuppressive Agents
- Imiquimod
- Sirolimus
|
Topics |
- Aged
- Aminoquinolines
(administration & dosage, therapeutic use)
- Antineoplastic Agents
(administration & dosage, therapeutic use)
- Graft Rejection
(drug therapy)
- Herpesvirus 8, Human
(isolation & purification)
- Humans
- Imiquimod
- Immunosuppression Therapy
- Immunosuppressive Agents
(adverse effects)
- Kidney Transplantation
(adverse effects)
- Sarcoma, Kaposi
(chemically induced, drug therapy, virology)
- Sirolimus
(adverse effects)
|